Pharmacokinetics of oltipraz in mutant Nagase analbuminemic rats

被引:6
作者
Bae, SK
Kang, HE
Kang, MK
Kim, JW
Kim, T
Lee, MG [1 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea
[3] CJ Corp, Inst Sci & Technol, R&D Ctr Pharmaceut, Ichon, South Korea
关键词
oltipraz; mutant Nagase analbuminemic rats; CYP1A2; pharmacokinetics; protein binding; metabolism; CYP enzymes;
D O I
10.1002/jps.20602
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Pharmacokinetic parameters of oltipraz were compared after intravenous (10 mg/kg) and oral (50 mg/kg) administration to control male Sprague-Dawely rats and mutant Nagase analbuminemic rats (NARs). In NARs, the expression and mRNA level of CYP1A2 increased, and oltipraz was mainly metabolized via Cyp1A1/2, 2B1/2, 2C11, 201, and 3A1/2 in male rats. Hence, it may be expected that the CL of oltipraz would be significantly faster in NARs. This was proven by the following results. After intravenous administration, the CL of oltipraz was significantly faster in NARs (125% increase) than controls due to significantly greater free fractions (unbound to plasma proteins) of oltipraz (197% increase) and significantly faster CLint for the disappearance of oltipraz (11.4% increase) in NARs, since oltipraz is an intermediate hepatic extraction ratio drug in rats. The V-ss was significantly larger in NARs (109% increase) and this could be due to significant increase in free fractions of oltipraz in NARs. After oral administration, the AUC of oltipraz was also significantly smaller in NARs (61.9% decrease). This could also be due to significant increase in free fractions of oltipraz and significantly faster CLint in NARs. However, this was not due to decrease in absorption in NARs. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 95:998-1005, 2006
引用
收藏
页码:998 / 1005
页数:8
相关论文
共 34 条
[1]   Effects of acute renal failure on the pharmacokinetics of oltipraz in rats [J].
Bae, SK ;
Lee, SJ ;
Kim, JW ;
Kim, YH ;
Kim, SG ;
Lee, MG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (09) :2353-2363
[2]   Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein-calorie malnutrition [J].
Bae, SK ;
Yang, SH ;
Kim, JW ;
Kim, T ;
Kwon, JW ;
Lee, MG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (07) :1484-1493
[3]   Hepatic and intestinal first-pass effects of Oltipraz in rats [J].
Bae, SK ;
Kim, JW ;
Kim, YH ;
Kim, YG ;
Kim, SG ;
Lee, MG .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2005, 26 (04) :129-134
[4]   Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics [J].
Bae, SK ;
Lee, SJ ;
Kim, YG ;
Kim, SH ;
Kim, JW ;
Kim, T ;
Lee, MG .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2005, 26 (03) :99-115
[5]   Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours [J].
Bae, SK ;
Lee, SJ ;
Kim, JW ;
Kim, YH ;
Kim, SG ;
Lee, MG .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2005, 26 (02) :77-83
[6]  
Bae SK, 2001, RES COMMUN MOL PATH, V110, P133
[7]  
BIEDER A, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1289
[8]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[9]   NEW CALCULATION METHOD OF MEAN TOTAL-BODY CLEARANCE OF DRUGS AND ITS APPLICATION TO DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (01) :90-91
[10]   NEW CALCULATION METHOD FOR MEAN APPARENT DRUG VOLUME OF DISTRIBUTION AND APPLICATION TO RATIONAL DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1067-1069